This conditional US FDA approval represents the first for the company's ExactVac DNA technology with ENABL adjuvant, the first DNA vaccine approved for influenza for veterinary use and among the first DNA vaccines approved in the US for food animals.
According to the company, the ENABL adjuvant technology helps realize that promise through more efficient delivery of DNA-based vaccines, which results in a higher absorption of the DNA vaccine and production of antigen, as well as broader immune response.
ENABL involves an interdisciplinary effort by social workers, public health officials, and school staff to implement the PSI curriculum in the public school system (for example, social workers are involved in advocating for PSI, which at times has involved battling resistance to teaching any type of pregnancy prevention in the schools).
An evaluation of the effectiveness of the ENABL program in Florida was conducted using a quasi-experimental design.
For the comparison group, attempts were made to recruit students from counties not participating in the ENABL program.
Despite equivocal results in California, ENABL holds promise as an intervention to reduce adolescent pregnancy.